Form 4: Replimune CEO Sells 10,000 Shares Under Pre-Arranged Trading Plan

Replimune's CEO, Sushil Patel, sold 10,000 shares of common stock at an average price of $12.42, as part of a pre-arranged trading plan.

Summary

• Sushil Patel, the CEO of Replimune Group, Inc., sold 10,000 shares of the company's common stock on December 16, 2024.
• The sale was executed at a weighted average price of $12.42 per share.
• The transactions occurred within a price range of $12.20 to $12.62.
• The sale was conducted under a pre-arranged trading plan adopted on April 3, 2024, to comply with Rule 10b5-1(c).
• Following the sale, Mr. Patel still beneficially owns 202,014 shares of Replimune common stock, including restricted stock units.
• He also holds options to acquire 513,750 shares, with 189,478 of those options currently exercisable.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly negative. While the sale was pre-planned, it could still raise concerns among some investors. However, the CEO's continued significant holdings mitigate this concern.

Positives

• The CEO's remaining holdings of 202,014 shares and 513,750 options indicate continued alignment with the company's success.
• The use of a pre-arranged trading plan suggests the sale was not based on any new material non-public information.

Negatives

• The sale of 10,000 shares by the CEO could be perceived negatively by some investors.

Risks

• Executive stock sales can sometimes be interpreted as a lack of confidence in the company's future prospects, although this sale was part of a pre-arranged plan.
• The market may react negatively to the sale, even if it was planned.

Management Comments

• The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on April 3, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often part of compensation packages or personal financial planning. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Replimune.
• Similar sales by executives at companies like Amgen, Gilead, and Regeneron are often reported through Form 4 filings.
• The size of the sale, 10,000 shares, is relatively small compared to the total holdings of the CEO and is not unusual for executives exercising stock options or selling shares for personal financial reasons.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale should mitigate this.
• The sale does not directly impact employees, customers, or suppliers.

Key Dates

Keywords

Replimune, Sushil Patel, stock sale, insider trading, Rule 10b5-1, executive compensation, share ownership, options